|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression |
ISO EXP |
Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine] fexofenadine results in decreased expression of ABCB11 mRNA |
CTD |
PMID:18245269 PMID:24852568 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance multiple interactions affects export |
ISO |
ABCB1 gene SNP affects the susceptibility to fexofenadine Itraconazole promotes the reaction [ABCB1 gene SNP affects the susceptibility to fexofenadine]; Plant Extracts promotes the reaction [ABCB1 protein results in increased transport of fexofenadine] ABCB1A protein affects the export of fexofenadine |
CTD |
PMID:12545142 PMID:15536457 PMID:15821041 PMID:16084853 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases export |
ISO |
[SLCO1B1 protein co-treated with ABCC2 protein] results in increased uptake of fexofenadine; [SLCO1B3 protein co-treated with ABCC2 protein] results in increased uptake of fexofenadine ABCC2 protein results in increased export of fexofenadine |
CTD |
PMID:18180276 PMID:18245269 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects transport multiple interactions |
ISO |
ABCC3 protein affects the transport of fexofenadine Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions decreases expression |
ISO |
[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CKM protein; [fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of IL1A protein; [fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased abundance of Cholesterol, LDL; [fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of CCL3 protein; [fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS2 mRNA; [fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS3 mRNA; APOE gene mutant form inhibits the reaction [fexofenadine results in decreased expression of MLXIPL mRNA]; APOE protein results in decreased susceptibility to [Dietary Fats co-treated with fexofenadine] fexofenadine results in decreased expression of APOE mRNA |
CTD |
PMID:24852568 PMID:25020133 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 mRNA]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of CCL11 protein] |
CTD |
PMID:15460210 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
decreases expression |
ISO |
fexofenadine results in decreased expression of CCL17 mRNA; fexofenadine results in decreased expression of CCL17 protein |
CTD |
PMID:21109747 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
decreases expression |
ISO |
fexofenadine results in decreased expression of CCL22 mRNA; fexofenadine results in decreased expression of CCL22 protein |
CTD |
PMID:21109747 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of CCL3 protein |
CTD |
PMID:25020133 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of CCL5 protein] |
CTD |
PMID:15460210 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
ISO |
[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CKM protein |
CTD |
PMID:25020133 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Ereg |
epiregulin |
decreases expression |
ISO |
fexofenadine results in decreased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [[Histamine binds to and results in increased activity of HRH1 protein] which results in increased expression of GUSB protein]; fexofenadine inhibits the reaction [Histamine results in increased expression of GUSB protein] |
CTD |
PMID:11238657 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
fexofenadine binds to and results in decreased activity of HRH1 protein; fexofenadine inhibits the reaction [[Histamine binds to and results in increased activity of HRH1 protein] which results in increased abundance of Calcium]; fexofenadine inhibits the reaction [[Histamine binds to and results in increased activity of HRH1 protein] which results in increased expression of GUSB protein] |
CTD |
PMID:11238657 PMID:19652466 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
fexofenadine results in decreased expression of ICAM1 protein |
CTD |
PMID:16270723 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions decreases expression |
ISO |
[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of IL1A protein fexofenadine results in decreased expression of IL1A mRNA |
CTD |
PMID:25020133 PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
fexofenadine results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [Histamine results in increased expression of IL6 protein] |
CTD |
PMID:11238657 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions increases activity |
ISO |
E 4031 inhibits the reaction [fexofenadine results in increased activity of KCNH2 protein mutant form]; fexofenadine inhibits the reaction [arsenic trioxide results in increased degradation of KCNH2 protein] |
CTD |
PMID:12070109 PMID:28521025 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
fexofenadine results in decreased phosphorylation of MAPK1 mRNA |
CTD |
PMID:21109747 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
fexofenadine results in decreased phosphorylation of MAPK3 mRNA |
CTD |
PMID:21109747 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
decreases expression |
ISO |
fexofenadine results in decreased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions decreases expression |
ISO |
APOE gene mutant form inhibits the reaction [fexofenadine results in decreased expression of MLXIPL mRNA] |
CTD |
PMID:24852568 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased activity of MMP2 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP2 mRNA]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP2 protein] |
CTD |
PMID:15663564 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP9 protein] |
CTD |
PMID:15663564 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] |
CTD |
PMID:15663564 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO |
[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS2 mRNA; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] fexofenadine results in decreased expression of NOS2 mRNA |
CTD |
PMID:17910814 PMID:25020133 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS3 mRNA |
CTD |
PMID:25020133 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein |
CTD |
PMID:20869355 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
fexofenadine results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
fexofenadine results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased activity of RELA protein] |
CTD |
PMID:15663564 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
fexofenadine results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression increases uptake multiple interactions |
ISO |
fexofenadine results in increased expression of SLCO1B2 mRNA SLCO1B3 protein results in increased uptake of fexofenadine [SLCO1B3 protein co-treated with ABCC2 protein] results in increased uptake of fexofenadine; Cyclosporine inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine] |
CTD |
PMID:18180276 PMID:18245269 PMID:24852568 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
fexofenadine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased expression of TIMP1 protein] |
CTD |
PMID:15663564 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased expression of TIMP2 protein] |
CTD |
PMID:15663564 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
fexofenadine inhibits the reaction [TNF protein results in increased activity of MMP2 protein]; fexofenadine inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; fexofenadine inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; fexofenadine inhibits the reaction [TNF protein results in increased activity of RELA protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of CCL11 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP2 mRNA]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP2 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; fexofenadine inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of TIMP1 protein]; fexofenadine inhibits the reaction [TNF protein results in increased expression of TIMP2 protein] |
CTD |
PMID:15460210 PMID:15663564 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|